For many years, the most effective wound care allografts came in mostly large sizes with few options in terms of sheet dimensions. This resulted in unnecessary costs and a large volume of waste, because once these products are freed from their sanitary packaging they must be used quickly in a sterile environment, and only on one patient at a time.

MiMedx has not only created a human amnion/chorion membrane (dHACM) allograft that is as effective or better at treating wounds than Apligraf or Dermagraft, but they also offer their EpiFix product in a multitude of dimensions, which significantly reduces waste and expenses for physicians treating patients with ailments such as diabetic foot wounds and venous leg wounds.